Sofia Ferreira

Sofia Ferreira

Auto-generated profile, based on publicly available information

Sofia Ferreira

CBIOS – Universidade Lusófona’s Research Center for Biosciences & Health Technologies, Lisbon, PT

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
Regina MenezesRegina Menezes
Regina Menezes
Ivo MartinsIvo Martins
Ivo Martins
SFSofia Ferreira
Sofia Ferreira
ARAna F Raimundo
Ana F Raimundo
Alzheimer’s disease (AD) is a neurodegenerative disorder that affects millions worldwide. Due to population ageing, the incidence of AD is increasing. AD patients develop cognitive decline and dementia, features for which is known, requiring permanent care. This poses a major socio-economic burden on healthcare systems as AD patients’ relatives and healthcare workers are forced to cope with rising numbers of affected people. Despite recent advances, AD pathological mechanisms are not fully understood. Nevertheless, it is clear that the amyloid beta (Aβ) peptide, which forms amyloid plaques in AD patients’ brains, plays a key role. Type 2 diabetes, the most common form of diabetes, affects hundreds of million people globally. Islet amyloid polypeptide (IAPP) is a hormone co-produced and secreted with insulin in pancreatic β-cells, with a key role in diabetes, as it helps regulate glucose levels and control adiposity and satiation. Similarly to Aβ, IAPP is very amyloidogenic, generating intracellular amyloid deposits that cause β-cell dysfunction and death. It is now clear that IAPP can also have a pathological role in AD, decreasing cognitive function. IAPP harms the blood-brain barrier, directly interacts and co-deposits with Aβ, promoting diabetes-associated dementia. IAPP can cause a metabolic dysfunction in the brain, leading to other diabetes-related forms of AD. Thus, here we discuss IAPP association with diabetes, Aβ and dementia, in the context of what we designate a “diabetes brain phenotype” AD hypothesis. Such approach helps to set a conceptual framework for future IAPP-based drugs against AD.

1 January 2022 in Biomedical and Biopharmaceutical Research
Verified
Journal Article
Closed access
SFSofia Ferreira
Sofia Ferreira
ARAna F. Raimundo
Ana F. Raimundo
IFInês Farrim
Inês Farrim
Regina MenezesRegina Menezes
Regina Menezes
Pancreatic deposition of Islet Amyloid PolyPeptide (IAPP) is a histopathological hallmark of type 2 diabetes. Inadequate processing of immature IAPP by proprotein convertases (PCs) leads to the accumulation of unprocessed forms, which in turn favors increased aggregate formation in pancreatic β-cells. Kexin 2 (Kex2) of Saccharomyces cerevisiae is the prototype of eukaryotic PCs family, but to date no direct correlations between Kex2 activity and preproIAPP processing in yeast have been reported. In this study we aimed to address the possible role of Kex2 on IAPP maturation as a tool to investigate the contribution of impaired processing towards IAPP proteototoxicity. Genetically modified S. cerevisiae models lacking the KEX2 gene and carrying different chimeric fusions of human IAPP linked to GFP were used. The cytotoxic effects of Kex2 ablation were assessed by means of growth curve analysis and cell viability assays using flow cytometry. IAPP protein profile was evaluated by immunoblotting assays using an anti-IAPP antibody. Intracellular IAPP aggregates were monitored by confocal fluorescence microscopy. Data showed that kex2 mutants exhibit growth defects, potentiated by preproIAPP-GFP, proIAPP-GFP and mature IAPP-GFP expression with an increased cytotoxicity for proIAPP-GFP. Notwithstanding, Kex2 absence does not seem to affect IAPP protein pattern nor the frequency/distribution of intracellular IAPP aggregates in yeast. Our findings suggest that Kex2 is not essential for IAPP processing in yeast, at least under the conditions tested. Keywords: Amylin, Islet Amyloid Polypeptide (IAPP), Kexin 2, Prohormone processing, Saccharomyces cerevisiae

2 July 2025 in bioRxiv
Verified
Preprint
Open access
MAMehmet Akdag
Mehmet Akdag
SFSofia Ferreira
Sofia Ferreira
Regina MenezesRegina Menezes
Regina Menezes
TSTessa Sinnige
Tessa Sinnige
The progressive loss of pancreatic β-cells is one of the defining features of Type 2 Diabetes Mellitus (T2DM), and is thought to be driven by the aggregation of islet amyloid polypeptide (IAPP). This highly amyloidogenic pancreatic hormone is co-secreted with insulin, and its elevated secretion can lead to toxic fibrillar aggregation. Despite numerous studies focusing on understanding the molecular mechanisms of IAPP aggregation, few therapeutic strategies exist to counter its toxicity. Urolithin B is a natural metabolite derived from the digestion and intestinal microbiota action on ellagitannin-rich foods. This compound was suggested to counteract IAPP aggregation and toxicity in silico and in yeast models expressing human IAPP. In this study, we focused on the protective potential of urolithin B using our previously characterised transgenic Caenorhabditis elegans IAPP-GFP model. We report that urolithin B reduces the levels of insoluble IAPP-GFP in the body wall muscle cells, while the mitochondrial association of IAPP-GFP remains unaltered. We show that the C. elegans model exhibits a reduced lifespan compared to controls, providing in vivo evidence of the toxic effects associated with IAPP-GFP expression. The lifespans of IAPP-GFP versus control animals were differentially modulated by urolithin B treatment, suggesting an interplay between the metabolite and IAPP-GFP mediated toxicity. To further elucidate the mode of action of urolithin B, we conducted in vitro assays and found no evidence of direct interaction with lipid-associated IAPP, suggesting that its effects are not mediated by interference with IAPP–membrane interactions. These results pave the way for further therapeutic developments targeting IAPP aggregation in T2DM.